About Importin subunit alpha-3
Importin subunit alpha-3 (KPNA4) is a protein
from Homo sapiens identified by UniProt accession
O00629, 521 residues long.
MolForge cross-references it against 0 known binders and
149 disease associations.
Target properties
| Protein name | Importin subunit alpha-3 |
| UniProt accession | O00629 |
| Gene | KPNA4 |
| Organism | Homo sapiens |
| Length | 521 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (149)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.53
- influenza · score 0.46
- clear cell renal carcinoma · score 0.25
- systolic blood pressure · score 0.16
- total cholesterol measurement · score 0.15
- myeloproliferative disorder · score 0.11
- pulse pressure measurement · score 0.10
- azoospermia · score 0.10
- eosinophil count · score 0.09
- type 2 diabetes mellitus · score 0.09
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O00629-F1 | alphafold | PREDICTED | 86.06 | — |
Amino-acid sequence (521 residues)
MADNEKLDNQ RLKNFKNKGR DLETMRRQRN EVVVELRKNK RDEHLLKRRN VPHEDICEDS DIDGDYRVQN TSLEAIVQNA SSDNQGIQLS AVQAARKLLS SDRNPPIDDL IKSGILPILV HCLERDDNPS LQFEAAWALT NIASGTSEQT QAVVQSNAVP LFLRLLHSPH QNVCEQAVWA LGNIIGDGPQ CRDYVISLGV VKPLLSFISP SIPITFLRNV TWVMVNLCRH KDPPPPMETI QEILPALCVL IHHTDVNILV DTVWALSYLT DAGNEQIQMV IDSGIVPHLV PLLSHQEVKV QTAALRAVGN IVTGTDEQTQ VVLNCDALSH FPALLTHPKE KINKEAVWFL SNITAGNQQQ VQAVIDANLV PMIIHLLDKG DFGTQKEAAW AISNLTISGR KDQVAYLIQQ NVIPPFCNLL TVKDAQVVQV VLDGLSNILK MAEDEAETIG NLIEECGGLE KIEQLQNHEN EDIYKLAYEI IDQFFSSDDI DEDPSLVPEA IQGGTFGFNS SANVPTEGFQ F
Explore Importin subunit alpha-3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets